» Articles » PMID: 16932426

Primary Aldosteronism: Diagnostic and Treatment Strategies

Overview
Specialty Nephrology
Date 2006 Aug 26
PMID 16932426
Citations 68
Authors
Affiliations
Soon will be listed here.
Abstract

Primary aldosteronism is caused by bilateral idiopathic hyperplasia in approximately two-thirds of cases and aldosterone-producing adenoma in one-third. Most patients with primary aldosteronism are normokalemic. In the clinical setting of normokalemic hypertension, patients who have resistant hypertension and hypertensive patients with a family history atypical for polygenic hypertension should be tested for primary aldosteronism. The ratio of plasma aldosterone concentration to plasma renin activity has been generally accepted as a first-line case-finding test. If a patient has an increased ratio, autonomous aldosterone production must be confirmed with an aldosterone suppression test. Once primary aldosteronism is confirmed, the subtype needs to be determined to guide treatment. The initial test in subtype evaluation is CT imaging of the adrenal glands. If surgical treatment is considered, adrenal vein sampling is the most accurate method for distinguishing between unilateral and bilateral adrenal aldosterone production. Optimal treatment for aldosterone-producing adenoma or unilateral hyperplasia is unilateral laparoscopic adrenalectomy. The idiopathic bilateral hyperplasia and glucocorticoid-remediable aldosteronism subtypes should be treated pharmacologically. All patients treated pharmacologically should receive a mineralocorticoid receptor antagonist, a drug type that has been shown to block the toxic effects of aldosterone on nonepithelial tissues.

Citing Articles

2023 Korean Endocrine Society Consensus Guidelines for the Diagnosis and Management of Primary Aldosteronism.

Ha J, Park J, Kim K, Kim J, Jung K, Lee J Endocrinol Metab (Seoul). 2023; 38(6):597-618.

PMID: 37828708 PMC: 10765003. DOI: 10.3803/EnM.2023.1789.


Anesthetic Implications in Managing a Case of Primary Hyperaldosteronism: A Case Report.

Ravi R, Prabhu M, Vamadevan B Cureus. 2023; 15(2):e35502.

PMID: 37007341 PMC: 10050601. DOI: 10.7759/cureus.35502.


Usefulness of Alternative Therapy with Hydrocortisone in the Postoperative Management of Severe Primary Aldosteronism.

Asakawa M, Takagi N, Hamada D, Yamasaki Y, Takaku Y, Kawada M Intern Med. 2023; 62(20):2981-2988.

PMID: 36858518 PMC: 10641202. DOI: 10.2169/internalmedicine.1279-22.


Primary Aldosteronism and COVID-19-related Management, Disease Severity, and Outcomes: A Retrospective Cohort Study.

Thomas T, Walpert A, Shen G, Dunderdale C, Srinivasa S J Endocr Soc. 2023; 7(4):bvad015.

PMID: 36824586 PMC: 9942545. DOI: 10.1210/jendso/bvad015.


Left adrenal aldosteronism coexisting with left paraaortic paraganglioma presenting as bilateral adrenal and left paraaortic tumors- comprehensive adrenal evaluation aiding perfect management: a case report.

Hsu Y, Lee C, Chen C, Hung C BMC Endocr Disord. 2022; 22(1):279.

PMID: 36371163 PMC: 9652807. DOI: 10.1186/s12902-022-01181-6.